{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:26:41Z","timestamp":1792009601408,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006469","name":"Macao Science and Technology Development Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research Program"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.phrs.2017.09.019","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T03:01:41Z","timestamp":1506567701000},"page":"153-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Role of tangeretin as a potential bioavailability enhancer for silybin: Pharmacokinetic and pharmacological studies"],"prefix":"10.1016","volume":"128","author":[{"given":"Zhong-Wen","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Zhuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Qiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen-ling","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Xiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.phrs.2017.09.019_bib0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S2221-1691(13)60060-X","article-title":"Bioavailability enhancers of herbal origin: an overview","volume":"3","author":"Kesarwani","year":"2013","journal-title":"Asia. Pac. J. Trop. Biomed."},{"key":"10.1016\/j.phrs.2017.09.019_bib0010","doi-asserted-by":"crossref","first-page":"637953","DOI":"10.1100\/2012\/637953","article-title":"A comprehensive review on pharmacotherapeutics of herbal bioenhancers","volume":"2012","author":"Dudhatra","year":"2012","journal-title":"Sci. World J."},{"issue":"2","key":"10.1016\/j.phrs.2017.09.019_bib0015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4103\/0975-9476.65073","article-title":"Bioenhancers: revolutionary concept to market","volume":"1","author":"Atal","year":"2010","journal-title":"J. Ayurveda Integr. Med."},{"key":"10.1016\/j.phrs.2017.09.019_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/736431","article-title":"Pharmacokinetic interactions of herbs with cytochrome p450 and p-glycoprotein","volume":"2015","author":"Cho","year":"2015","journal-title":"Evidence-Based Complement. Altern. Med.: eCAM"},{"issue":"4","key":"10.1016\/j.phrs.2017.09.019_bib0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1055\/s-2006-957450","article-title":"Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers","volume":"64","author":"Shoba","year":"1998","journal-title":"Planta Med."},{"key":"10.1016\/j.phrs.2017.09.019_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.fitote.2014.05.005","article-title":"Role of herbal bioactives as a potential bioavailability enhancer for Active Pharmaceutical Ingredients","volume":"97","author":"Ajazuddin","year":"2014","journal-title":"Fitoterapia"},{"issue":"2","key":"10.1016\/j.phrs.2017.09.019_bib0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1572-0241.1998.00139.x","article-title":"Milk thistle (Silybum marianum) for the therapy of liver disease","volume":"93","author":"Flora","year":"1998","journal-title":"Am. J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.phrs.2017.09.019_bib0040","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1039\/b300099k","article-title":"Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum)","volume":"1","author":"Kim","year":"2003","journal-title":"Org. Biomol. Chem."},{"issue":"10","key":"10.1016\/j.phrs.2017.09.019_bib0045","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/ptr.3207","article-title":"Milk thistle in liver diseases: past, present, future","volume":"24","author":"Abenavoli","year":"2010","journal-title":"Phytother. Res."},{"issue":"2","key":"10.1016\/j.phrs.2017.09.019_bib0050","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3892\/mmr.2014.2821","article-title":"Ginsenoside-Rg5 induces apoptosis and DNA damage in human cervical cancer cells","volume":"11","author":"Liang","year":"2015","journal-title":"Mol. Med. Rep."},{"issue":"9","key":"10.1016\/j.phrs.2017.09.019_bib0055","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.freeradbiomed.2012.02.008","article-title":"Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"52","author":"Loguercio","year":"2012","journal-title":"Free Radical Biol. Med."},{"issue":"1","key":"10.1016\/j.phrs.2017.09.019_bib0060","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.etap.2014.05.005","article-title":"Hepatoprotective effect of silymarin on di(2-ethylhexyl)phthalate (DEHP) induced injury in liver FL83B cells","volume":"38","author":"Lo","year":"2014","journal-title":"Environ. Toxicol. Pharm."},{"issue":"3","key":"10.1016\/j.phrs.2017.09.019_bib0065","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1053\/j.gastro.2009.11.053","article-title":"Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase","volume":"138","author":"Ahmed-Belkacem","year":"2010","journal-title":"Gastroenterology"},{"issue":"13","key":"10.1016\/j.phrs.2017.09.019_bib0070","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1073\/pnas.0914009107","article-title":"Identification of hepatoprotective flavonolignans from silymarin","volume":"107","author":"Polyak","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.phrs.2017.09.019_bib0075","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3851\/IMP1942","article-title":"Intravenous silibinin as \u2018rescue treatment' for on-treatment non-responders to pegylated interferon\/ribavirin combination therapy","volume":"16","author":"Rutter K","year":"2011","journal-title":"Antivir. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2017.09.019_bib0080","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/0091270009347475","article-title":"Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C","volume":"50","author":"Hawke","year":"2010","journal-title":"J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.phrs.2017.09.019_bib0085","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1124\/dmd.110.034793","article-title":"20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions","volume":"38","author":"Zhang","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.phrs.2017.09.019_bib0090","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1124\/dmd.107.017566","article-title":"Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract","volume":"36","author":"Wen Z","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.phrs.2017.09.019_bib0095","first-page":"134","article-title":"Study on dose-Linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay","volume":"30","author":"Weyhenmeyer","year":"1992","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2017.09.019_bib0100","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF03188811","article-title":"Comparative pharmacokinetics of silipide and silymarin in rats","volume":"18","author":"Morazzoni","year":"1993","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"12","key":"10.1016\/j.phrs.2017.09.019_bib0105","doi-asserted-by":"crossref","first-page":"593","DOI":"10.5414\/CPP41593","article-title":"Comparative bioavailability of silibinin in healthy male volunteers","volume":"41","author":"Kim","year":"2003","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"18","key":"10.1016\/j.phrs.2017.09.019_bib0110","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.3748\/wjg.v17.i18.2288","article-title":"Silybin and the liver: from basic research to clinical practice","volume":"17","author":"Loguercio","year":"2011","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.phrs.2017.09.019_bib0115","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jama.2012.8265","article-title":"Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial","volume":"308","author":"Fried","year":"2012","journal-title":"JAMA: J. Am. Med. Assoc."},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2017.09.019_bib0120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/01635581.2013.785004","article-title":"Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer","volume":"65","author":"Mateen","year":"2013","journal-title":"Nutr. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2017.09.019_bib0125","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3109\/03602530903491881","article-title":"Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity","volume":"42","author":"Swift","year":"2010","journal-title":"Drug Metab. Rev."},{"issue":"10","key":"10.1016\/j.phrs.2017.09.019_bib0130","first-page":"1277","article-title":"P-glycoprotein-mediated in vitro biliary excretion in sandwich-cultured rat hepatocytes","volume":"29","author":"Annaert","year":"2001","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.phrs.2017.09.019_bib0135","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/jpet.110.165852","article-title":"Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes","volume":"334","author":"Lee","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2017.09.019_bib0140","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/S0022-3565(24)38310-7","article-title":"Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes","volume":"259","author":"Liu","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2017.09.019_bib0145","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22010142","article-title":"Role of UDP-Glucuronosyltransferase 1A1 in the metabolism and pharmacokinetics of silymarin flavonolignans in patients with HCV and NAFLD","volume":"22","author":"Xie","year":"2017","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.phrs.2017.09.019_bib0150","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1271\/bbb.130404","article-title":"Transport mechanisms for soy isoflavones and microbial metabolites dihydrogenistein and dihydrodaidzein across monolayers and membranes","volume":"77","author":"Kobayashi","year":"2013","journal-title":"Biosci. Biotechnol. Biochem."},{"issue":"6","key":"10.1016\/j.phrs.2017.09.019_bib0155","first-page":"1037","article-title":"Absorption and metabolism of biologically active genistein derivatives in colon carcinoma cell line (Caco-2)","volume":"71","author":"Papaj","year":"2014","journal-title":"Acta Pol. Pharm."},{"issue":"33","key":"10.1016\/j.phrs.2017.09.019_bib0160","doi-asserted-by":"crossref","first-page":"28110","DOI":"10.1039\/C5RA28018D","article-title":"Enhanced hepatic-targeted delivery via oral administration using nanoliposomes functionalized with a novel DSPE-PEG-cholic acid conjugate","volume":"6","author":"Li","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.phrs.2017.09.019_bib0165","series-title":"Center for Drug Evaluation and Research (CDER), Guidance for Industry, Drug Interaction Studies\u2014study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations","author":"FDA","year":"2012"},{"issue":"11","key":"10.1016\/j.phrs.2017.09.019_bib0170","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1124\/dmd.108.021790","article-title":"Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2)","volume":"36","author":"Miranda","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.phrs.2017.09.019_bib0175","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jep.2012.09.044","article-title":"Herbal medicines for the prevention of alcoholic liver disease: a review","volume":"144","author":"Ding","year":"2012","journal-title":"J. Ethnopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2017.09.019_bib0180","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/antiox4010204","article-title":"Silymarin as a natural antioxidant: an overview of the current evidence and perspectives","volume":"4","author":"Surai","year":"2015","journal-title":"Antioxidants"},{"issue":"4","key":"10.1016\/j.phrs.2017.09.019_bib0185","first-page":"308","article-title":"Silymarin, a promising pharmacological agent for treatment of diseases","volume":"14","author":"Karimi","year":"2011","journal-title":"Iran. J. Basic Med. Sci."},{"key":"10.1016\/j.phrs.2017.09.019_bib0190","first-page":"e116","volume":"4","author":"SS","year":"2015","journal-title":"Nat. Bioenhancers: Curr. OutlookClin. Pharmacol. Biopharm."},{"issue":"1","key":"10.1016\/j.phrs.2017.09.019_bib0195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MOL.0b013e32835c07fd","article-title":"Citrus flavonoids and lipid metabolism","volume":"24","author":"Assini","year":"2013","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.phrs.2017.09.019_bib0200","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.phrs.2016.04.003","article-title":"Tangeretin a citrus pentamethoxyflavone, antagonizes ABCB1-mediated multidrug resistance by inhibiting its transport function","volume":"110","author":"Feng","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.phrs.2017.09.019_bib0205","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3136\/fstr.20.629","article-title":"Cellular antioxidant activity and pharmacokinetic study of polymethoxylated flavonoids in extract of citrus reticulata \u2018Chachi' peel","volume":"20","author":"Yuen","year":"2014","journal-title":"Food Sci Technol Res"},{"issue":"5","key":"10.1016\/j.phrs.2017.09.019_bib0210","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/clpt.2012.79","article-title":"A perspective on efflux transport proteins in the liver","volume":"92","author":"Kock","year":"2012","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817307892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817307892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T22:41:47Z","timestamp":1750891307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661817307892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":42,"alternative-id":["S1043661817307892"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2017.09.019","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of tangeretin as a potential bioavailability enhancer for silybin: Pharmacokinetic and pharmacological studies","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2017.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}